scholarly journals Prolactin May Not Play a Role in Primary Antiphospholipid (Hughes') Syndrome

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Manoel Tavares Neves Junior ◽  
Carlos Ewerton Maia Rodrigues ◽  
Jozelio Freire de Carvalho
Keyword(s):  
Antiphospholipid Antibodies ◽  
Healthy Subjects ◽  
Clinical Manifestations ◽  
Primary Antiphospholipid Syndrome ◽  
Healthy Controls ◽  
Laboratory Findings ◽  
Autoimmune Rheumatic Diseases ◽  
Clinical Associations ◽  
The Relationship ◽  
Hughes Syndrome

The relationship between prolactin (PRL) and the immune system has been demonstrated in the last two decades and has opened new windows in the field of immunoendocrinology. However, there are scarce reports about PRL in primary antiphospholipid syndrome (pAPS). The objective of this study was to evaluate PRL levels in patients with pAPS compared to healthy controls and to investigate their possible clinical associations. Fifty-five pAPS patients according to Sapporo criteria were age- and sex-matched with 41 healthy subjects. Individuals with secondary causes of hyperprolactinemia (HPRL) were excluded; demographic, biometric, and clinical data, PRL levels, antiphospholipid antibodies, inflammatory markers, and other routine laboratory findings were analyzed. PRL levels were similar between pAPS and healthy controls (8.94±7.02versus8.71±6.73 ng/mL,P=.876). Nine percent of the pAPS patients and 12.1% of the control subjects presented HPRL (P=.740). Comparison between the pAPS patients with hyper- and normoprolactinemia revealed no significant differences related to anthropometrics, clinical manifestations, medications, smoking, and antiphospholipid antibodies (P>.05). This study showed that HPRL does not seem to play a role in clinical manifestations of the pAPS, differently from other autoimmune rheumatic diseases.

scholarly journals Central and cerebrovascular effects of leg crossing in humans with sympathetic failure

2010 ◽  
Vol 118 (9) ◽  
pp. 573-581 ◽  
Author(s):  
Mark P.M. Harms ◽  
Wouter Wieling ◽  
Willy N.J.M. Colier ◽  
Jacques W.M. Lenders ◽  
Niels H. Secher ◽  
...  
Keyword(s):  
Arterial Pressure ◽  
Healthy Subjects ◽  
Cerebral Perfusion ◽  
Peripheral Resistance ◽  
Transcranial Doppler Ultrasound ◽  
Blood Velocity ◽  
Healthy Controls ◽  
Age And Gender ◽  
And Gender ◽  
The Relationship

Leg crossing increases arterial pressure and combats symptomatic orthostatic hypotension in patients with sympathetic failure. This study compared the central and cerebrovascular effects of leg crossing in patients with sympathetic failure and healthy controls. We addressed the relationship between MCA Vmean (middle cerebral artery blood velocity; using transcranial Doppler ultrasound), frontal lobe oxygenation [O2Hb (oxyhaemoglobin)] and MAP (mean arterial pressure), CO (cardiac output) and TPR (total peripheral resistance) in six patients (aged 37–67 years; three women) and age- and gender-matched controls during leg crossing. In the patients, leg crossing increased MAP from 58 (42–79) to 72 (52–89) compared with 84 (70–95) to 90 (74–94) mmHg in the controls. MCA Vmean increased from 55 (38–77) to 63 (45–80) and from 56 (46–77) to 64 (46–80) cm/s respectively (P<0.05), with a larger rise in O2Hb [1.12 (0.52–3.27)] in the patients compared with the controls [0.83 (−0.11 to 2.04) μmol/l]. In the control subjects, CO increased 11% (P<0.05) with no change in TPR. By contrast, in the patients, CO increased 9% (P<0.05), but also TPR increased by 13% (P<0.05). In conclusion, leg crossing improves cerebral perfusion and oxygenation both in patients with sympathetic failure and in healthy subjects. However, in healthy subjects, cerebral perfusion and oxygenation were improved by a rise in CO without significant changes in TPR or MAP, whereas in patients with sympathetic failure, cerebral perfusion and oxygenation were improved through a rise in MAP due to increments in both CO and TPR.

The Role of Hyperleukocytosis in Predicting the Severity of Pertussis

2020 ◽  
Author(s):  
Xiao-Ying Wu ◽  
chuan gan
Keyword(s):  
Heart Rate ◽  
Respiratory Rate ◽  
Bacterial Infections ◽  
Clinical Manifestations ◽  
Organ Damage ◽  
Clinical Analysis ◽  
Laboratory Findings ◽  
Wbc Count ◽  
The Relationship

Abstract Background: Few reports have described the relationship between WBC count and the severity of pertussis or the timing of ET in patients with hyperleukocytosis.Methods: A retrospective clinical analysis of infants with pertussis and a WBC exceeding 30*10^9/L was performed.Results: A total of 158 patients were enrolled in the study. There were significant differences in the clinical manifestations of cyanosis, fever, highest respiratory rate, and highest heart rate. There were significant differences in all complications except for pulmonary hypertension. In laboratory findings, there were significant differences in organ damage (myocardial markers, ALT), increased inflammation indicators (CRP, PCT), and the incidence of combined bacterial infections. There were significant differences in ICU stay length, mechanical ventilation use, days hospitalized, days until cough relief and days until the WBC fell below 25*10^9/L. A WBC count >55.38 *10^9/L was calculated as the cutoff value with 88.2% sensitivity and 23.4% specificity in predicting ET. A respiratory rate of 59 breaths/min had 94.1% sensitivity and 36.7% specificity in predicting ET. A heart rate of 159 beats/min had 100% sensitivity and 38.1% specificity in predicting ET.Conclusion: WBC count is related to the severity of pertussis. We recommend that ET is considered when the patient’s WBC count exceeds 55*10^9/L, breathing exceeds 60 breaths/min, and/or heart rate exceeds 160 beats/min.

scholarly journals Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Jozélio Freire de Carvalho ◽  
Sandra Gofinet Pasoto ◽  
Simone Appenzeller
Keyword(s):  
Risk Factors ◽  
Regression Analysis ◽  
Physical Examination ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Clinical Manifestations ◽  
Primary Antiphospholipid Syndrome ◽  
Current Smoking ◽  
Significant Comparison ◽  
Standard Interview

Objectives. To evaluate the frequency of seizures in primary antiphospholipid syndrome (PAPS) and their possible clinical and laboratory associations.Methods. Eighty-eight PAPS patients (Sydney’s criteria) were analyzed by a standard interview, physical examination and review of medical charts. Risk factors for seizures, clinical manifestations, associated comorbidities, and antiphospholipid antibodies were evaluated.Results. Nine (10.2%) patients with seizures were identified, 77.8% had convulsions onset after PAPS diagnosis. Mean age, gender, and race were comparable in groups with or without seizures. Interestingly, a higher frequency of current smoking (44.4 versus 10.1%, ) was observed in the first group. Stroke, Sneddon’s syndrome, and livedo reticularis were more frequent in PAPS patients with seizures than those without seizures, although not statistically significant (). Comparison between patients with seizures onset after PAPS diagnosis () and those without convulsions () demonstrated a higher frequency of current smoking (42.9 versus 10%, ) and stroke in the first group (71.4 versus 30.4%, ). Regression analysis confirmed that smoking () and stroke () were independently associated to seizures.Conclusion. About 10.2% of PAPS patients had convulsions, predominantly after PAPS diagnosis, and seizures were associated to current smoking and stroke.

scholarly journals The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity

2021 ◽  
Author(s):  
Otavio Cabral Marques ◽  
Gilad Halpert ◽  
Lena F Schimke ◽  
Yuri Ostrinski ◽  
Israel Zyskind ◽  
...  
Keyword(s):  
Severe Disease ◽  
Clinical Manifestations ◽  
Renin Angiotensin System ◽  
Clinical Severity ◽  
Therapeutic Interventions ◽  
Ras Signaling ◽  
Healthy Controls ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
The Relationship

The coronavirus disease 2019 (COVID-19) can evolve to clinical manifestations resembling systemic autoimmune diseases, with the presence of autoantibodies that are still poorly characterized. To address this issue, we performed a cross-sectional study of 246 individuals to determine whether autoantibodies targeting G protein-coupled receptors (GPCRs) and renin-angiotensin system (RAS)-related molecules were associated with COVID-19-related clinical outcomes. Moderate and severe patients exhibited the highest autoantibody levels, relative to both healthy controls and patients with mild COVID-19 symptoms. Random Forest, a machine learning model, ranked anti-GPCR autoantibodies targeting downstream molecules in the RAS signaling pathway such as the angiotensin II type 1 and Mas receptor, and the chemokine receptor CXCR3 as the three strongest predictors of severe disease. Moreover, while the autoantibody network signatures were relatively conserved in patients with mild COVID-19 compared to healthy controls, they were disrupted in moderate and most perturbed in severe patients. Our data indicate that the relationship between autoantibodies targeting GPCRs and RAS-related molecules associates with the clinical severity of COVID-19, suggesting novel molecular pathways for therapeutic interventions.

scholarly journals Urokinase Gene 3′-UTR T/C Polymorphism Is Associated with Malignancy and ESRD in Idiopathic Membranous Nephropathy

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Cheng-Hsu Chen ◽  
Shih-Yin Chen ◽  
Kuo-Hsiung Shu ◽  
Mei-Chin Wen ◽  
Chi-Hung Cheng ◽  
...  
Keyword(s):  
Membranous Nephropathy ◽  
Healthy Subjects ◽  
Clinical Manifestations ◽  
Idiopathic Membranous Nephropathy ◽  
Genotype Distribution ◽  
Chain Reaction ◽  
Common Causes ◽  
Disease Entities ◽  
Polymerase Chain ◽  
The Relationship

Idiopathic membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults, and 25% of MN patients proceed to ESRD. Urokinase plasminogen activator (uPA) may play an important role in reducing renal fibrosis. This study was conducted to clarify the relationship between uPA gene polymorphisms and clinical manifestations of MN. We recruited 91 biopsy-diagnosed MN patients and 105 healthy subjects. Genotyping of uPA gene 3′-UTR T/C polymorphism was performed by polymerase chain reaction methods. The genotype distribution had no effect on the development of MN. Thirteen patients (15.9%;P=0.008) acquired malignancies and seventeen (20.7%;P=0.006) patients progressed to ESRD with the C/C genotype, but no patients with the T/C genotype did. In conclusion, we demonstrated that the presence of the uPA gene 3′-UTR C/C genotype was associated with ESRD as well as acquired malignancies in MN patients. These findings should prompt specific considerations for the treatment of MN patients to maintain a balance between treating disease entities and protecting the immune system from cancers.

Primary Antiphospholipid Syndrome with Livedo Reticularis is Linked to Female Sex and Stroke and Negatively Associated with Thyroid Disease

2021 ◽  
Vol 17 ◽  
Author(s):  
Jozélio Freire Carvalho ◽  
Roberto Paulo Correia de Araujo ◽  
Carlos Mauricio Cardeal Mendes ◽  
Thelma Larocca Skare
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Medication Use ◽  
Livedo Reticularis ◽  
Primary Antiphospholipid Syndrome ◽  
Profile Data ◽  
Laboratory Findings ◽  
Transversal Study ◽  
Common Manifestation

Aim: To study the clinical and laboratory findings between patients with primary Antiphospholipid Syndrome (pAPS) with and without LR. Background: Livedo Reticularis (LR) is a common manifestation of Antiphospholipid Syndrome (APS). Although no previous study evaluated patients with and without LR. Methods: A transversal study including 66 pAPS patients was performed. Demographical, anthropometric, medication use, antiphospholipid antibodies profile data were evaluated, and LR's clinical and laboratory features. Patients were subdivided into one of two groups: pAPS with LR and pAPS without LR. Results: Both groups were alike concerning demographics and anthropometrics. Interestingly, the frequency of stroke (28.5 vs. 7.5%, p=0.04), as well as of Sneddon’s syndrome (100 vs. 30.0%, p<0.0001), were higher in pAPS with LR than the other group. Conversely, patients in the pAPS without LR group had more thyroidopathy than those in the pAPS with LR group (80% vs. 50% %, p=0.03). Conclusion: Patients with pAPS and LR have more stroke and seem to be protected from thyroidopathy. Careful follow-up of these patients is therefore advised.

scholarly journals Primary antiphospholipid syndrome in children: experience from two tertiary centres in South India

2019 ◽  
Vol 6 (2) ◽  
pp. 243
Author(s):  
Mahesh Janarthanan ◽  
Dhaarani Jayaraman ◽  
Julius Scott ◽  
M. S. Latha ◽  
Saravanan Margabandhu ◽  
...  
Keyword(s):  
Clinical Features ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Clinical Manifestations ◽  
Fetal Loss ◽  
Primary Antiphospholipid Syndrome ◽  
Retrospective Case ◽  
Case Record ◽  
Vascular Thrombosis ◽  
Immunologic Profile

Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the presence of episodes of vascular thrombosis, recurrent fetal loss and other clinical features in the presence of antiphospholipid antibodies. The aim of the study was to analyze the clinical manifestations and immunologic profile of children presenting with APS.Methods: Authors did a retrospective case record study of patients admitted with thrombotic events between September 2013 and August 2018 and identified patients with positive antiphospholipid antibodies. Children who had clinical features of active lupus were not included.Results: The clinical and immunologic profile of 7 pediatric patients presenting with APS over 5 years from 2013 to 2018 were analysed. Symptoms secondary to vascular thrombosis were limb swelling, stroke, gangrene of toes and Budd Chiari syndrome.Conclusions:APS though rare should be considered in the differential diagnosis of children presenting with thrombotic events. They need long term anticoagulants to prevent further episodes. 

Sign in / Sign up

Export Citation Format

Share Document